http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 15:13:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/ME+Therapeutics+announces+private+placement+to+raise+up+to+%24500%2C000/26598401.html <p>ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) announced a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit.</p> <p>Each unit consists of one common share and one non-transferrable common share purchase warrant. The warrants are exercisable into additional shares at $2.00 each for three years from issuance, subject to an acceleration clause if the volume weighted average share price reaches or exceeds $3.00 for ten consecutive trading days.</p> <p>The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S. http://www.streetinsider.com/Equity+Offerings/ME+Therapeutics+announces+private+placement+to+raise+up+to+%24500%2C000/26598401.html Wed, 03 Jun 2026 15:13:18 -0400 METX O.61277869 Q9T http://www.streetinsider.com/Equity+Offerings/ME+Therapeutics+announces+private+placement+to+raise+up+to+%24500%2C000/26598401.html <p>ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) announced a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit.</p> <p>Each unit consists of one common share and one non-transferrable common share purchase warrant. The warrants are exercisable into additional shares at $2.00 each for three years from issuance, subject to an acceleration clause if the volume weighted average share price reaches or exceeds $3.00 for ten consecutive trading days.</p> <p>The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S. http://www.streetinsider.com/Equity+Offerings/ME+Therapeutics+announces+private+placement+to+raise+up+to+%24500%2C000/26598401.html Wed, 03 Jun 2026 15:13:18 -0400 METX O.61277869 Q9T http://www.streetinsider.com/Equity+Offerings/ME+Therapeutics+announces+private+placement+to+raise+up+to+%24500%2C000/26598401.html <p>ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) announced a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit.</p> <p>Each unit consists of one common share and one non-transferrable common share purchase warrant. The warrants are exercisable into additional shares at $2.00 each for three years from issuance, subject to an acceleration clause if the volume weighted average share price reaches or exceeds $3.00 for ten consecutive trading days.</p> <p>The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S. http://www.streetinsider.com/Equity+Offerings/ME+Therapeutics+announces+private+placement+to+raise+up+to+%24500%2C000/26598401.html Wed, 03 Jun 2026 15:13:18 -0400 METX O.61277869 Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html <p class="bwalignc"> <b>NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES</b> </p> <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Announces+Private+Placement/26598400.html Wed, 03 Jun 2026 15:13:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Press+Releases/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver. </p><p> During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity. </p><p> Dr. Dhanji http://www.streetinsider.com/Business+Wire/ME+Therapeutics+to+Pitch+at+CSE+Capital+Tech+Connect+During+Web+Summit+Vancouver/26449555.html Thu, 07 May 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs. </p><p> ME Therapeutics continues to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html Wed, 29 Apr 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs. </p><p> ME Therapeutics continues to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html Wed, 29 Apr 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs. </p><p> ME Therapeutics continues to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html Wed, 29 Apr 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs. </p><p> ME Therapeutics continues to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to http://www.streetinsider.com/Press+Releases/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html Wed, 29 Apr 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs. </p><p> ME Therapeutics continues to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html Wed, 29 Apr 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs. </p><p> ME Therapeutics continues to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to http://www.streetinsider.com/Business+Wire/ME+Therapeutics+Provides+Scientific+Update+on+In+Vivo+CAR+and+Therapeutic+mRNA+Programs/26389221.html Wed, 29 Apr 2026 09:00:00 -0400 METX O.61277869 Q9T Q9T